Rapid development of broadly influenza neutralizing antibodies through redundant mutations

The neutralizing antibody response to influenza virus is dominated by antibodies that bind to the globular head of haemagglutinin, which undergoes a continuous antigenic drift, necessitating the re-formulation of influenza vaccines on an annual basis. Recently, several laboratories have described a new class of rare influenza-neutralizing antibodies that target a conserved site in the haemagglutinin stem. Most of these antibodies use the heavy-chain variable region VH1-69 gene, and structural data demonstrate that they bind to the haemagglutinin stem through conserved heavy-chain complementarity determining region (HCDR) residues. However, the VH1-69 antibodies are highly mutated and are produced by some but not all individuals, suggesting that several somatic mutations may be required for their development. To address this, here we characterize 197 anti-stem antibodies from a single donor, reconstruct the developmental pathways of several VH1-69 clones and identify two key elements that are required for the initial development of most VH1-69 antibodies: a polymorphic germline-encoded phenylalanine at position 54 and a conserved tyrosine at position 98 in HCDR3. Strikingly, in most cases a single proline to alanine mutation at position 52a in HCDR2 is sufficient to confer high affinity binding to the selecting H1 antigen, consistent with rapid affinity maturation. Surprisingly, additional favourable mutations continue to accumulate, increasing the breadth of reactivity and making both the initial mutations and phenylalanine at position 54 functionally redundant. These results define VH1-69 allele polymorphism, rearrangement of the VDJ gene segments and single somatic mutations as the three requirements for generating broadly neutralizing VH1-69 antibodies and reveal an unexpected redundancy in the affinity maturation process.

[1]  J. Mascola,et al.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.

[2]  J. Foote,et al.  Kinetic and affinity limits on antibodies produced during immune responses. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Weiss,et al.  A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies , 2007, Influenza and other respiratory viruses.

[4]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[5]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[6]  F. Delbos,et al.  Multiple layers of B cell memory with different effector functions , 2009, Nature Immunology.

[7]  P. S. Andersen,et al.  Limits for Antibody Affinity Maturation and Repertoire Diversification in Hypervaccinated Humans , 2011, The Journal of Immunology.

[8]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[9]  M. Neuberger,et al.  Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. , 1998, Immunity.

[10]  R. Maul,et al.  Different B Cell Populations Mediate Early and Late Memory During an Endogenous Immune Response , 2011, Science.

[11]  W. Ollier,et al.  Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. , 2002, Rheumatology.

[12]  Thomas B. Kepler,et al.  Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody , 2012, Proceedings of the National Academy of Sciences.

[13]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[14]  M. Eichelberger,et al.  A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. , 2010, Vaccine.

[15]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[16]  E. Sasso,et al.  A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles. , 1993, The Journal of clinical investigation.

[17]  Andrew S. Bennett,et al.  Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses , 2014, PLoS pathogens.

[18]  Tongqing Zhou,et al.  Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.

[19]  T. Kipps,et al.  Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. , 1996, The Journal of clinical investigation.

[20]  C. Nusbaum,et al.  High-Resolution Description of Antibody Heavy-Chain Repertoires in Humans , 2011, PloS one.

[21]  J. Whittle,et al.  Structural and genetic basis for development of broadly neutralizing influenza antibodies , 2012, Nature.

[22]  K. Subbarao,et al.  B Cell Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H1N1 Influenza Virus Vaccination , 2013, Clinical and Vaccine Immunology.

[23]  Ning Ma,et al.  IgBLAST: an immunoglobulin variable domain sequence analysis tool , 2013, Nucleic Acids Res..

[24]  F. Baldanti,et al.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody , 2013, Nature.

[25]  J. Yewdell,et al.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.

[26]  A. Kajaste-Rudnitski,et al.  Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease , 2013, AIDS.

[27]  Chin-fen Yang,et al.  Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. , 2003, Virology.

[28]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[29]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[30]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[31]  Andrew C. R. Martin,et al.  Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. , 2008, Molecular immunology.

[32]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[33]  Marie-Paule Lefranc,et al.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis , 2008, Nucleic Acids Res..

[34]  Rodrigo Lopez,et al.  A new bioinformatics analysis tools framework at EMBL–EBI , 2010, Nucleic Acids Res..

[35]  Feng Wang,et al.  Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation , 2013, Proceedings of the National Academy of Sciences.

[36]  Yoshimasa Takahashi,et al.  Both mutated and unmutated memory B cells accumulate mutations in the course of the secondary response and develop a new antibody repertoire optimally adapted to the secondary stimulus. , 2013, International immunology.

[37]  Klaus Rajewsky,et al.  Intraclonal generation of antibody mutants in germinal centres , 1991, Nature.

[38]  L. Staudt,et al.  Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.